ClinicalTrials.gg
Sign In

Carcinoma, Renal Cell clinical trials

The registry lists 2,038 studies for Carcinoma, Renal Cell across more than 10 countries. 395 are recruiting or about to start. 1,435 of them are mainly about Carcinoma, Renal Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Clear-cell metastatic renal cell carcinoma too: 2,064 studies, 405 open.

ClinicalTrials.gov finds 2,514 studies for Carcinoma, Renal Cell. How that becomes 2,035 here

This page counts the studies the registry files under Carcinoma, Renal Cell, and those it files under no condition that list Carcinoma, Renal Cellthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 2,514Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −26Filed under a narrower condition, counted on its own pageClear-cell metastatic renal cell carcinoma 26
  3. −35List Carcinoma, Renal Cell as a condition, but the registry did not file them under itMost often written as “Advanced Renal Cell Carcinoma” (8), “Renal Cell Cancer Metastatic” (6), and “Renal Cell Carcinoma Metastatic” (4). The registry filed them under other conditions only, most often Kidney Neoplasms (12) and Prostatic Neoplasms (6).
  4. −419Match it another way86 name it in the title, 3 in a keyword, and 330 by a synonym or other text the search reads.
  5. 2,034Counted here and found by its search73 of them list Carcinoma, Renal Cell in their own words; the registry filed them under no condition.
  6. +1
    Counted here, but its search does not find them
  7. 2,035The count on this page

Get an email when these change. Save the Carcinoma, Renal Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
943
Recruiting
307
Terminated
289
Active, not recruiting
170
Status unknown
141
Not yet recruiting
81

Phase

Phase 2
860
Phase 1
626
Phase 3
130
Early Phase 1
33
Phase 4
26

Where

United States
1,142
China
234
France
201
United Kingdom
168
Spain
164
Canada
160

Who runs them

National Cancer Institute (NCI) (116) · Pfizer (75) · M.D. Anderson Cancer Center (56) · Novartis Pharmaceuticals (35) · Bristol-Myers Squibb (32) · Bayer (29) · Memorial Sloan Kettering Cancer Center (29) · Merck Sharp & Dohme LLC (25)

What is being tested here

Drugs under test in Carcinoma, Renal Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Pembrolizumab15645
Lenvatinib12228
Cabozantinib11641
Nivolumab9862
Axitinib9437
Zanzalintinib839
Toripalimab619
Ipilimumab5427
Belzutifan5518
Anti-CD70 CAR-expressing T Lymphocytes505

Drug classes tested here Immune checkpoint inhibitors 65 open · Tyrosine kinase inhibitors (TKIs) 56 open · Angiogenesis inhibitors 4 open · Antimetabolites 4 open · mTOR inhibitors 3 open

Coming up

44phase 3 studies under way
166studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger. 20 (7%) take children under 18. 0 (0%) are for women only and 2 (1%) for men only; 19 (6%) take healthy volunteers.

Recruiting studies that take each age, of 307
AgeWomenMen
1014 (5%)14 (5%)
18296 (96%)298 (97%)
30300 (98%)302 (98%)
40300 (98%)302 (98%)
50300 (98%)302 (98%)
65302 (98%)304 (99%)
75299 (97%)301 (98%)
85268 (87%)270 (88%)

Across all 2,038 studies, recruiting or not: 7% stop at 75 or younger and 2% at 65; 8% take children; <1% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Carcinoma, Renal Cell studies take

Of 230 phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 58 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 150 mo32–72 · 219 studies49 mo32–63 · 138 studies54 mo31–76 · 81 studies
Phase 1/264 mo45–87 · 111 studies67 mo44–78 · 70 studies64 mo45–132 · 41 studies
Phase 258 mo33–94 · 230 studies33 mo24–52 · 47 studies67 mo41–98 · 183 studies
Phase 356 mo42–89 · 61 studies49 mo31–59 · 35 studies—
Interventional, no phase45 mo22–114 · 126 studies—48 mo24–114 · 119 studies
Observational50 mo33–94 · 139 studies48 mo36–91 · 42 studies50 mo26–241 · 97 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Started recruiting1

Results posted1

Stopped4

Newly registered11

Show 6 more

Studies

Recruiting first, then most recently updated. Showing 50 of 2,038. Browse all 2,038 → or search them.